Director Dealing

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 26 April 2022 that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 3 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,500 pence per Ordinary Share (the “Purchase”). The shares were purchased under a dividend reinvestment plan (DRIP).

Following the Purchase, Bruce Hiscock has a beneficial interest in 424 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
 

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: [phone]
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane	Corporate Finance ECM	Tel: [phone]

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bruce Hiscock
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Bioventix Plc
b)	LEI	213800225MHX7LZQY108
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 5 pence each
	Identification code	GB00B4QVDF07
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	3 Ordinary Shares 3,500 pence
d)	Aggregated information: ·Aggregated volume ·Price	Purchase of 3 Ordinary Shares at 3,500 pence each
e)	Date of the transaction	25 April 2022
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)